ASMQ Meeting

[December 1st, 2011]
Rio de Janeiro
The meeting “Artesunate-Mefloquine (ASMQ) Fixed-Dose Combination (FDC), an additional tool in the armamentarium to control malaria in Latin-America” was held in parallel with DNDi‘s annual partners’ meeting in Rio de Janeiro.

Children with HIV/AIDS Falling Through the Cracks of Treatment Scale-Up Efforts

[Geneva, Switzerland/New York, USA – 1 December 2011]
Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day (1 December 2011). Although treatment coverage for adults has been steadily climbing and has now reached approximately half of those in need, coverage for children is lagging far behind, highlighted the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organization that has recently launched a new paediatric HIV drug development programme.

Major Project Launched to Support India and Bangladesh’s National Control Programmes in Implementing New Treatments to Boost Kala-Azar Elimination Strategies

[Geneva, Switzerland, and New Delhi, India – 7 November 2011]
A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world’s highest.

Aprobado el registro del nuevo tratamiento para niños con mal de Chagas

[Río de Janeiro y Recife (Brasil) y Ginebra (Suiza) – 2 de diciembre de 2011]
Hoy, durante la celebración de la 4ta. Reunión de Socios de DNDi en Rio de Janeiro, Brasil, el Dr. Carlos Gadelha, Secretario de Ciencia, Tecnología y Productos Estratégicos del Ministerio de Salud de Brasil, anunciaron que la Agencia Nacional de Vigilancia Sanitaria (ANVISA) concedió el registro a la nueva formulación en dosis pediátrica de benznidazol. El registro de esta nueva formulación, desarrollada a través de la asociación entre el Laboratorio Farmacéutico Público de Pernambuco (LAFEPE) de Brasil y la Iniciativa Medicamentos para las Enfermedades Olvidadas (DNDi), será publicado el 12 de Diciembre de 2011.
[English] [Português]

Novo Tratamento para Crianças com a Doença de Chagas Aprovado pela ANVISA

[Rio de Janeiro e Recife, Brasil, e Genebra, Suíça – 02 de Dezembro de 2011]
Hoje, durante a IV Reunião de Parceiros da DNDi, no Rio de Janeiro, o Secretário de Ciência, Tecnologia e Produtos Estratégicos do Ministério da Saúde, Carlos Gadelha, anunciou que a Agencia Nacional de Vigilância Sanitária (ANVISA) concedeu o registro da formulação em dose pediátrica do benznidazol. O registro desta nova dose pediátrica do benznidazol, produzida por meio de uma parceria entre o Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) e a iniciativa Medicamentos para Doenças Negligenciadas (DNDi), será publicado no dia 12 de dezembro de 2011.
[English] [Español]

SSG&PM SP: Nuevo tratamiento contra el kala-azar, la enfermedad parasitaria más mortal después de la malaria. Se necesita apoyo urgente que permita a los gobiernos poner en marcha el tratamiento y controlar la enfermedad

[Nairobi, 23 de septiembre de 2011]

África oriental lucha en estos momentos contra el peor brote de kala-azar de la última década. Gracias a una colaboración llevada a cabo en toda la región a través de la Plataforma para la Leishmaniasis en el Este de África (LEAP, por sus siglas en inglés) se ha desarrollado una nueva combinación terapéutica (EGS + PM) más barata y que disminuye casi a la mitad el ciclo de tratamiento – de 30 días de inyecciones a 17 días- . Los países del África oriental están tomando las medidas regulatorias necesarias para usar este tratamiento dentro de sus programas, pero los expertos alertan de que pocos pacientes se beneficiarán sin los fondos internacionales necesarios y el interés y el apoyo a los gobiernos para su puesta en marcha.
[English]

Progress in India in Medical Research New Treatments for Neglected Diseases from Research to Implementation

[New Delhi, India – December 3, 2010]
Over 150 Indian and international health researchers, policy makers, experts from 22 countries met on December 3rd, at the Constitutional Club in New Delhi for the 3rd International Partners meeting organized by Drugs for Neglected Diseases initiative (DNDi) in collaboration with Indian Council for Medical Research (ICMR) to stimulate greater regional research partnership to fight the most neglected diseases such as Kala-azar sleeping sickness, malaria and Chagas disease.

ASTMH 2010

[November 3-7, 2010]
Atlanta, USA
The Drugs for Neglected Diseases initiative (DNDi) will participate in several activities at ASTMH 2010, including a joint symposium with Central Drug Research Institute (CDRI) on Visheral Leishmaniasis (VL) in the Indian Continent, a second symposium on VL in East Africa, a satellite symposium on Challenges and Successes of the FACT Project through Innovative Partnerships for the development of Artesunate Combination Therapies for Malaria, as well as several oral presentations.